7 June 2023, 02:35 | Janice Quek

CFRA Downgrades Opinion of Shares of Gitlab Inc. to Buy from Strong Buy

We raise our target to $52 from $49 on a P/S of 13.8x our next-12-month sales projection of $571M, below its three-year average on a softer demand environment and higher execution risks. We narrow our FY 24 (Jan.) LPS view to -$0.15 from -$0.23, cut FY 25 EPS to $0.03 from $0.07, and drop our FY 26 estimate. GTLB reported Q1 revenue of $127M, above consensus by $9.05M, while non-GAAP EPS of -$0.06

7 June 2023, 01:49 | Jonathan Sakraida

CFRA Keeps Hold Rating on Shares of Chart Industries, Inc.

We adjust our 12-month price target to $148 from $165, valuing shares at 13.5x our 2024 EBITDA estimate, which is more in line with the company’s pre-pandemic forward EV/EBITDA multiple. We believe this is appropriate given elevated execution risk and potential challenges surrounding the Howden acquisition amid an uncertain and dynamic macro environment. The acquisition has driven GTLS’s lever

6 June 2023, 23:59 | Daniel Rich, CFA

CFRA Raises View on Shares of HCA Healthcare, Inc. to Buy from Hold

Our 12-month target remains $301, reflecting a 2023 EV/EBITDA of 10x, above HCA's recent historical averages. We raise our 2023 adjusted EPS estimate $0.22 to $18.12 and raise 2024's by $0.57 to $19.91. Looking at recent performance, facilities remains as one of the strongest areas within health care, up 7.1% YTD as of May 31. We see recent momentum with facilities maintaining the strongest 12-mo